Celltrion’s Remsima SC Biosimilar Starts Strong In EU5 Countries
New Study Follows Approval For IBD Indications Last Year
Celltrion is capitalizing on the earlier strength of its intravenous Remsima formulation to make waves with its innovative subcutaneous version, according to the results of a new study sampling nearly 250 gastroenterologists in EU5 countries.
